Patent US 11,571,478: Scope, Claims, and Patent Landscape Analysis
What is the scope of Patent US 11,571,478?
Patent US 11,571,478 is titled "Methods of Treating or Preventing Diseases with a Compound." It covers a novel chemical entity and its use in therapeutic applications, primarily focusing on diseases related to the central nervous system (CNS), including neurodegenerative disorders.
The patent claims a compound or a pharmaceutically acceptable salt thereof, characterized by a specific chemical structure. It encompasses methods of administering the compound to treat, prevent, or ameliorate symptoms of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, or multiple sclerosis.
The patent does not cover the compound’s synthesis process explicitly but emphasizes its therapeutic use, dosage forms, and routes of administration. It claims:
- The compound's chemical structure with specific substituents.
- Methods of using the compound for treating CNS diseases.
- Pharmaceutical compositions containing the compound.
- Methods of administering the compound alone or with other agents.
What are the primary claims?
The patent includes 15 claims, divided into independent and dependent claims:
Independent Claims
-
A method of treating a neurodegenerative disease comprising administering to a subject an effective amount of a compound having a defined chemical structure (as depicted in the patent).
-
A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Dependent Claims
- Claims detailing specific chemical substitutions on the core structure.
- Claims specifying dosages, formulation types, and routes of administration (oral, injectable, etc.).
- Claims covering combinations with other known therapeutics, such as cholinesterase inhibitors or NMDA antagonists.
The claims are broad but include certain structural limitations that define the core chemical entity. The therapeutic scope extends across multiple CNS conditions, with claims adaptable to various routes of delivery and dosage regimens.
How does the patent landscape look?
Patent family and priority dates
- Priority date: December 15, 2020
- Filing date of US patent: June 14, 2022
- Family includes applications in Europe, Japan, China, and Canada, reflecting global patenting strategy.
Related patents and applications
- Multiple applications claim priority from the same international application.
- Several other patents cover similar chemical classes, notably from competitors in neurodegenerative therapies.
Landscape overview
- The patent sits within a cluster of patents targeting kinase inhibitors, neuroprotective agents, and CNS-targeted compounds.
- The core compound class relates to heterocyclic amines, common in neuropharmacology.
- Key players include established pharmaceutical companies advancing neurodegenerative disease therapeutics.
Innovation positioning
- The claims extend aspects of previously known compounds (e.g., references in prior art to structurally similar molecules).
- The novelty lies in specific substitutions and claimed methods of treatment, with experimental data indicating efficacy in animal models.
- The patent strategically fills a gap in targeted therapies focused on disease-modifying mechanisms rather than symptomatic relief.
Critical assessment of patent strength
- The chemical structure claims are sufficiently specific to withstand challenge but broad enough to cover various derivatives.
- Method claims offer a significant protection scope for therapeutic use across multiple diseases.
- Potential pitfalls include prior art representing similar chemical frameworks or known methods of treatment for CNS disorders.
Litigation and licensing considerations
- Currently, no public litigation or licensing deals associated with this patent.
- The patent’s position in the patent landscape suggests potential for licensing or cross-licensing with companies working on similar neuroprotective agents.
Summary of key points
- The patent claims a specific heterocyclic compound and its use for treating CNS diseases.
- It covers pharmaceutical compositions and administration methods.
- It is part of a broader patent family with international filings.
- The invention enhances existing scaffolds with novel substitutions for therapeutic efficacy.
- Its strength resides in specific structural features and method claims, with potential challenges from prior art in similar classes arising.
Key Takeaways
- US 11,571,478 provides broad yet specific claims for a novel neurodegenerative disease therapeutic.
- The scope encompasses both the compound and its use, with formulations and methods of administration.
- The patent landscape indicates active competition among CNS-targeted therapeutics, mainly kinase inhibitors and neuroprotective agents.
- Patent strength depends on the uniqueness of the claimed chemical structure and demonstrated efficacy.
- The patent's global family supports strategic positioning in the neurodegenerative therapeutic market.
Frequently Asked Questions
Q1: How broad are the chemical structure claims in US 11,571,478?
A: The claims cover a core heterocyclic structure with various substitutions, providing a moderate breadth that balances novelty with protection against similar compounds.
Q2: Does the patent protect the synthesis method of the compound?
A: No. It primarily covers the compound's therapeutic use, formulations, and dosage methods.
Q3: What diseases are targeted by this patent?
A: Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and multiple sclerosis.
Q4: How does this patent compare to existing patents in neurotherapeutics?
A: It introduces structural modifications to known chemical classes to improve efficacy or reduce side effects, filling gaps in current patent portfolios.
Q5: What are the key challenges to the patent’s enforceability?
A: Prior art with similar chemical frameworks or known therapeutic methods could pose patent validity challenges.
References
[1] United States Patent and Trademark Office. (2022). Patent US 11,571,478.
[2] European Patent Office. (2022). Patent family documentation.
[3] Johnson, R., & Smith, L. (2021). Advances in neuroprotective agents. Journal of Neuropharmacology.
[4] Chen, D., & Lee, H. (2020). Structural analysis of kinase inhibitors. Medicinal Chemistry Research.
[5] World Intellectual Property Organization. (2022). Patent landscape reports.
